Dr Brendon Chua is a viral and translational immunologist who completed his PhD at the University of Melbourne. His research focuses on defining innate and adaptive immune-mediated mechanisms that underpin the control of respiratory viral infections, including influenza and SARS-CoV-2, and translating these findings into commercial outcomes. He has held research positions at Monash University, the Ludwig Institute for Cancer Research and the CRC for Polymers, as well as placements in the vaccine industry. He is also an affiliated Associate Professor of Hokkaido University and leading member of Japan’s Global Institute of Collaborative Research & Education (GI-CoRE) consortium.
Brendon is recognised for this work on defining protective immune responses to respiratory infection, vaccination and anti-viral interventions using human and mouse disease models. Translational outcomes from his work have led to human clinical trials and large animal testing as well as inventorships on numerous patents. His achievements are recognised in over 50 publications and awards of research grants as well as industry funding. He is also a founder of ENA Respiratory and Axelia Oncology, both established to develop the use of agonists that can stimulate innate immunity against respiratory viral infections in the upper respiratory tract and cancers.
Professor Katherine Kedzierska’s team researches immunity to viral infections, especially the newly emerged SARS-CoV-2 and influenza viruses. Her work spans basic research from mouse experiments to human immunity through to clinical settings, with particular focus on understanding universal CD8+ T cell immunity to respiratory viruses. Her studies aim to identify key correlates of severe and fatal respiratory disease in high-risk groups including children, the elderly, Australian First Nations people, pregnant women and patients with co-morbidities.
Full University of Melbourne profile